RecoveryInvestigational

Chrysalin (TP508)

Topical, Subcutaneous injection

Overview

Chrysalin, also known as TP508, is a 23-amino acid synthetic peptide derived from the receptor-binding domain of human thrombin. It is designed to activate non-proteolytic thrombin receptors on endothelial cells, fibroblasts, and osteoblasts, thereby promoting angiogenesis, granulation tissue formation, and bone repair.

Mechanism of Action

The peptide retains thrombin's tissue repair signaling properties without procoagulant activity..

Research Summary & Key Findings

Phase II trials in diabetic foot ulcers and fracture healing showed some evidence of accelerated wound closure and callus formation. However, subsequent phase III trials did not demonstrate statistically significant improvements in primary endpoints, and commercial development has been limited.

Clinical Status

Investigational

Chrysalin (TP508) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

TopicalSubcutaneous injection

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers Chrysalin (TP508) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Chrysalin (TP508).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.